ALT

#2800
Altimmune, Inc. - Common Stock
3.1 1 USD
-0.04%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
3.11
3.11
Intervallo Annuale
2.56
6.44
Variazione giornaliera
-4.01%
Variazione Mensile
+6.87%
Variazione di 6 mesi
-25.95%
Variazione Annuale
-18.37%
Chiusura Precedente
3.2 4
Open
3.1 1
Minimo
3.1 1
Massimo
3.1 1
Volume
89
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Altimmune, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Altimmune, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Altimmune, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Altimmune, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Altimmune, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Altimmune, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Altimmune, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Altimmune, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Altimmune, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Altimmune, Inc. current report, Q1 FY2026
8-K

Altimmune, Inc. current report, 11 June 2013

Full document

Business Context and Reporting Period

This Form 8-K filing by PharmAthene, Inc. (not Altimmune, Inc.) reports on the results of the Annual Meeting of Stockholders held on June 11, 2013. The filing details the election of directors and the outcomes of shareholder proposals regarding executive compensation and auditor ratification.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

Director Elections

Shareholders elected the following directors to serve until the next annual meeting. All nominees received significant support, though broker non-votes were substantial across all candidates:

  • John Gill: 15,813,278 votes for; 849,203 withheld.
  • Brian A. Markison: 15,869,072 votes for; 793,409 withheld.
  • Joel McCleary: 15,870,772 votes for; 791,709 withheld.
  • Eric I. Richman: 15,673,272 votes for; 989,209 withheld.
  • Jeffrey W. Runge, M.D.: 15,877,357 votes for; 785,124 withheld.
  • Mitchel Sayare, Ph.D.: 15,878,657 votes for; 783,824 withheld.
  • Derace L. Schaffer, M.D.: 15,144,963 votes for; 1,517,518 withheld.
  • Steven St. Peter, M.D.: 15,875,061 votes for; 787,420 withheld.

Shareholder Proposals

  • Say-on-Pay Vote: Approved with 15,021,614 votes for, 1,594,802 against, and 46,065 abstentions.
  • Auditor Ratification: Ratified the appointment of Ernst & Young LLP with 35,570,688 votes for and 3,809,413 against.
  • Say-on-Pay Frequency: Shareholders voted to hold future Say-on-Pay votes every two years (6,604,672 votes), compared to every three years (6,476,876 votes) or every year (2,922,794 votes).

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to reporting the mechanics and results of the shareholder vote.

Investor Verification Checklist

  • Verify the company name is PharmAthene, Inc., as the input metadata incorrectly referenced Altimmune, Inc.
  • Confirm the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2013.
  • Note the established frequency for future Say-on-Pay votes is every two years.
  • Review the proxy statement for details on executive compensation referenced in the advisory vote.

Notizie